XENLETA

Peak

lefamulin acetate

NDAORALTABLETPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Mar 25, 2033
85 months away
Patent Expiry
Mar 25, 2033
Exclusivity Expiry
Aug 19, 2029

Patent Records (3)

Patent #ExpiryTypeUse Code
8153689
Mar 19, 2028
SubstanceProduct
9120727
May 23, 2031
SubstanceProduct
8071643
Mar 25, 2033
SubstanceProduct